阿奇霉素和穿心莲内酯磺化物的联合应用对肺炎支原体肺炎患儿临床疗效和血清炎症因子的影响

摘要/Abstract

摘要： 目的：探讨穿心莲内酯磺化物（ADS）与阿奇霉素的联合应用对肺炎支原体肺炎（MPP）患儿临床疗效和血清炎症因子的影响。方法：将100例MPP患儿随机分为试验组和对照组，试验组给予ADS联合阿奇霉素静滴治疗，对照组只给予同等剂量阿奇霉素静滴治疗；检测试验组和对照组患儿治疗前(t0)、治疗后24小时(t1)及治疗后7天(t2)血清肿瘤坏死因子-α（TNF-α）和白介素-17（IL-17）的浓度，并进行对比分析，同时比较患儿临床症状包括发热、咳嗽等的转归。结果：试验组住院时间、发热持续时间、湿啰音消失时间及咳嗽持续时间和对照组相比均缩短（P<0.05）；t1与t0相比，试验组患儿血清TNF-α和IL-17下降(P<0.05)，对照组患儿血清TNF-α和IL-17无显著差异(P>0.05)，试验组较对照组改善更明显( P<0.05)；t2与t0相比，试验组和对照组患儿血清TNF-α和IL-17均下降(P<0.05)，试验组较对照组改善更明显( P<0.05)。结论： ADS与阿奇霉素联合治疗MPP，可以提高MPP的疗效；其机制可能与改变机体的细胞因子水平、调节免疫功能有关；且ADS能显著下调MPP治疗早期炎症因子水平。

Abstract: Objective： To discuss the combined effect of andrographolide sulfonated (ADS) injection and azithromycin on serum inflammatory factors and its clinical effect on pediatric mycoplasma pneumonia(MPP). Methods： 100 cases of hospitalized MPP children were selected and randomly divided into two groups. Intravenous azithromycin combined with intravenous ADS was administered to the experimental group and the control group was given equal doses of azithromycin. Serum content of TNF-α and IL-17 of the two groups were tested before initiating the treatment (t0)， 24 h after initiating the treatment (t1) and 7 days after treatment(t2). Results： The length of hospital stay， fever duration time， rales disappearance time， cough disappearance time in experimental group were all significantly less than that in control group (P<0. 05). Compared with t0， the serum TNF-α and IL-17 level at t1 appeared to be significantly decreased in the experimental group (P<0.05) whereas the serum TNF-α and IL-17 level at t1 in the control group was not significant different (P>0.05). The difference between two groups was significant (P<0.05). Compared with t0，The serum TNF-α and IL-17 level of the two groups at time of t2 were all decreased and the defferences were significant (P<0.05). The decrease of the serum TNF-a and IL-17 level from t0 to t2 of experimental group was more than that of the control group（P<0.05）. Conclusion： Intravenous azithromycin combined with intravenous ADS may be able to improve therapeutic effect on MPP； its mechanism may be the change in cytokines level and immune function regulation. Also， ADS in treating pediatric mycoplasma pneumonia exhibit significant adjustment on inflammatory factors level， especially in the early stage of the treatment.

赵晨,白燕,邬平,刘贤文,金润铭. 阿奇霉素和穿心莲内酯磺化物的联合应用对肺炎支原体肺炎患儿临床疗效和血清炎症因子的影响[J]. .

ZHAO Chen,BAI Yan,WU Ping,LIU Xianwen and JIN Runming. The Combined Effect of Andrographolide Sulfonated Injection and Azithromycin on Serum Inflammatory Factors and Its Clinical Effect on Pediatric[J]. .

参考文献

1. 夏怡丰, 穿心莲内酯（Andro）抗炎机制的研究. 2004, 中国科学院研究生院（上海生命科学研究院）.
2. Iruretagoyena, M.I., et al., Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. Journal of Pharmacology and Experimental Therapeutics, 2005. 312(1): p. 366-372.
3. 廖世煌, et al., 病毒净滴眼液对单纯疱疹性角膜炎疗效研究. 中国中医眼科杂志, 1992(01): p. 7-9.
4. 亓翠玲, 王丽京, and 周鑫磊, 穿心莲内酯抗肿瘤作用机制的研究进展. 中国中药杂志, 2007(20): p. 2095-2097.
5. Yu, B.-C., W.-C. Chen, and J.-T. Cheng, Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats. Planta medica, 2003. 69(12): p. 1075-1079.
6. Wang, Z.F., et al., [Literature review on premarketing and postmarketing evidence of xiyanping injection]. Zhongguo Zhong Yao Za Zhi, 2014. 39(18): p. 3637-40.
7. Xiong, N., et al., [Effect of the Combination of Xiyanping and Cefazolin on the Function of Neutrophils in Mice]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2015. 32(5): p. 1079-82.
8. Yin, X.P., et al., [Correlation analysis on combined medication with of Xiyanping injection in treatment of lung infection in real world]. Zhongguo Zhong Yao Za Zhi, 2015. 40(12): p. 2440-4.
9. Zhao, Y., et al., Clinical application analysis of andrographolide total ester sulfonate injection, a traditional Chinese medicine licensed in China. J Huazhong Univ Sci Technolog Med Sci, 2017. 37(2): p. 293-299.
10. Gaillat, J., et al., Community epidemiology of Chlamydia and Mycoplasma pneumoniae in LRTI in France over 29 months. Eur J Epidemiol, 2005. 20(7): p. 643-51.
11. Yang, E., T. Altes, and S.A. Anupindi, Early Mycoplasma pneumoniae infection presenting as multiple pulmonary masses: an unusual presentation in a child. Pediatr Radiol, 2008. 38(4): p. 477-80.
12. Cao, B., et al., Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin Respir J, 2015.
13. 梁锦枝, et al., 喜炎平联合阿奇霉素治疗支原体肺炎疗效的Meta分析. 中国实验方剂学杂志, 2014(18): p. 220-224.
14. Yamada, M., et al., Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J, 2012. 31(4): p. 409-0.
15. Okazaki, N., et al., Characteristics of Macrolide‐Resistant Mycoplasma pneumoniae Strains Isolated from Patients and Induced with Erythromycin In Vitro. Microbiology and immunology, 2001. 45(8): p. 617-620.
16. Okada, T., et al., Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clinical infectious diseases, 2012. 55(12): p. 1642-1649.
17. Xin, D., et al., Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrobial agents and chemotherapy, 2009. 53(5): p. 2158-2159.
18. Wu, P.S., et al., Epidemiology and clinical manifestations of children with macrolide‐resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatric pulmonology, 2013. 48(9): p. 904-911.
19. 鲍芳, et al., 儿童大环内酯耐药支原体肺炎的临床特点及治疗转归. 中华结核和呼吸杂志, 2013. 36(10): p. 756-761.
20. Liu, Y., et al., Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagnostic microbiology and infectious disease, 2010. 67(4): p. 355-358.
21. Zhou, Y., et al., More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrobial agents and chemotherapy, 2014. 58(2): p. 1034-1038.
22. Ma, Z., et al., Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China. Pediatric pulmonology, 2014. 49(7): p. 695-700.
23. 吴绮, 阿奇霉素治疗小儿支原体肺炎的临床疗效. 当代医学, 2013(06): p. 126-127.
24. 王海燕, 阿奇霉素联合喜炎平治疗儿童支原体肺炎的疗效及机制探讨. 现代中西医结合杂志, 2013(20): p. 2221-2223.
25. Guo, H., et al., Imbalance of peripheral blood Th17 and Treg responses in children with refractory Mycoplasma pneumoniae pneumonia. Journal of Infection and Chemotherapy, 2016. 22(3): p. 162-166.
26. 段世玲, 肺炎支原体肺炎患儿血清炎症细胞因子的检测及临床意义. 中国现代医生, 2011(19): p. 107-108+114.
27. Li, W., et al., Th1/Th2 Cytokine Profile and Its Diagnostic Value in Mycoplasma pneumoniae Pneumonia. Iran J Pediatr, 2016. 26(1): p. e3807.
28. 陈陵海, et al., 喜炎平注射液治疗小儿细菌性肺炎的随机对照研究及其对血清细胞因子的影响. 儿科药学杂志, 2013(11): p. 31-33.
29. 贾艳敏, et al., 小儿手足口病采用喜炎平联合阿昔洛韦治疗的临床疗效观察及对细胞因子的影响. 河北医药, 2015(23): p. 3584-3586.
30. 郝瑞卿, 侯素香, and 谭海明, 喜炎平佐治小儿支原体肺炎相关血清炎性因子检测及其机制研究. 中国社区医师(医学专业), 2011(18): p. 107-108.
31. Bettelli, E., et al., Induction and effector functions of T^ sub H^ 17 cells. Nature, 2008. 453(7198): p. 1051.
32. Das, J., et al., Transforming growth factor β is dispensable for the molecular orchestration of Th17 cell differentiation. Journal of Experimental Medicine, 2009. 206(11): p. 2407-2416.
33. Langrish, C.L., et al., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Journal of Experimental Medicine, 2005. 201(2): p. 233-240.
34. Zou, W. and N.P. Restifo, TH17 cells in tumour immunity and immunotherapy. Nature Reviews Immunology, 2010. 10(4): p. 248-256.
35. Ogura, H., et al., Interleukin-17 Promotes Autoimmunity by Triggering a Positive-Feedback Loop via Interleukin-6 Induction. Immunity, 2008. 29(4): p. 628-636.

快速检索引用检索图表检索高级检索